A three-dose course of AstraZeneca’s COVID-19 vaccine is effective against the omicron coronavirus variant, the pharmaceutical company said on Thursday, citing data from an Oxford University lab study.
The study, yet to be published in a peer-reviewed medical journal, showed antibody levels against imicron after the booster shot were higher than antibodies in people who had been infected with and recovered naturally from COVID-19.
For all the latest headlines follow our Google News channel online or via the app.
After a three-dose course of the vaccine, neutralizing levels against omicron were similar to those against the virus’s delta variant after two doses, the company added.
The Anglo-Swedish drugmaker said researchers at Oxford University who carried out the study were independent from those who worked on the vaccine, Vaxzevria, with AstraZeneca.
Read more:
Omicron hospitalization risk is far below delta’s in two studies
Pfizer pill becomes first US-authorized home COVID-19 treatment
No country can boost its way out of pandemic: WHO chief
